Stock Events

Stock Events

Opus Genetics 

€3.92
72
+€0.08+2.08% Friday 14:37

Statistics

Day High
3.92
Day Low
3.9
52W High
4.83
52W Low
1.072
Volume
100
Avg. Volume
-
Mkt Cap
326.13M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q1 2026
Q2 2026
Next
-0.64
-0.46
-0.29
-0.11
Expected EPS
-0.1236831872
Actual EPS
N/A

Financials

-345.29%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
12.4MRevenue
-42.82MNet Income

Analyst Ratings

8.65Average Price Target
The highest estimate is 12.14.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
91%
Hold
9%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow R3X1.MU. It's not an investment recommendation.
NVIDIA
11
NVDA
Amazon
10
AMZN
Apple
9
AAPL
Microsoft
9
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
EyePoint
EYPT
Mkt Cap386.23M
EyePoint Pharmaceuticals focuses on developing treatments for eye diseases, directly competing with Ocuphire's focus on ophthalmic diseases.
Bausch Health Companies
BHC
Mkt Cap2.36B
Bausch Health Companies, through its eye health division, offers products that compete in the broader ophthalmology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals offers treatments for eye diseases, including Eylea for macular degeneration, directly competing with Ocuphire's products.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, with its ophthalmology division, competes in developing treatments for eye conditions, including those targeted by Ocuphire.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline, through its investments in ophthalmology, competes in the same therapeutic areas as Ocuphire.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, owning Allergan, an eye care product company, competes in the ophthalmology market, affecting Ocuphire's market share.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a portfolio of ophthalmology treatments, competing with Ocuphire in the eye disease treatment market.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO Inc. focuses on gene therapy for retinal diseases, directly competing with Ocuphire Pharma's focus on eye disorders.

About

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Show more...
CEO
George Magrath
Employees
28
Country
United States
ISIN
US67577R1023
WKN
000A2QG4Z

Listings

MU
DE
R3X1.MU
STU
DE
R3X1.STU
F
DE
R3X1.F
XNAS
US
IRD

0 Comments

Share your thoughts

FAQ

What is Opus Genetics stock price today?▼
The current price of R3X1.MU is €3.92 EUR — it has increased by +2.08% in the past 24 hours. Watch Opus Genetics stock price performance more closely on the chart.
What is Opus Genetics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Opus Genetics stocks are traded under the ticker R3X1.MU.
Is Opus Genetics stock price growing?▼
R3X1.MU stock has risen by +16.67% compared to the previous week, the month change is a +20.99% rise, over the last year Opus Genetics has showed a +265.67% increase.
What is Opus Genetics market cap?▼
Today Opus Genetics has the market capitalization of 326.13M
When is the next Opus Genetics earnings date?▼
Opus Genetics is going to release the next earnings report on November 17, 2026.
What were Opus Genetics earnings last quarter?▼
R3X1.MU earnings for the last quarter are -0.12 EUR per share, whereas the estimation was -0.14 EUR resulting in a +10.64% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Opus Genetics revenue for the last year?▼
Opus Genetics revenue for the last year amounts to 12.4M EUR.
What is Opus Genetics net income for the last year?▼
R3X1.MU net income for the last year is -42.82M EUR.
How many employees does Opus Genetics have?▼
As of September 05, 2026, the company has 28 employees.
In which sector is Opus Genetics located?▼
Opus Genetics operates in the Health & Wellness sector.
When did Opus Genetics complete a stock split?▼
Opus Genetics has not had any recent stock splits.
Where is Opus Genetics headquartered?▼
Opus Genetics is headquartered in DURHAM, United States.